Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study to Compare the Bioavailability and Pharmacokinetics of Cyclosporine After Intravenous Administration of NEUROSTAT, a CREMOPHOR EL-free Lipid Emulsion, and SANDIMMUNE Injection (a Suspension of Cyclosporine in CREMOPHOR EL) in Healthy Volunteers ; An Open-label, Subject-blind, Laboratory-blind, Single-dose (5 mg/kg Infusion), Randomised, Two-period Crossover Tolerability Study Carried Out in Healthy Male and Female Subjects

Next Previous
Search
Trial Profile

A Study to Compare the Bioavailability and Pharmacokinetics of Cyclosporine After Intravenous Administration of NEUROSTAT, a CREMOPHOR EL-free Lipid Emulsion, and SANDIMMUNE Injection (a Suspension of Cyclosporine in CREMOPHOR EL) in Healthy Volunteers ; An Open-label, Subject-blind, Laboratory-blind, Single-dose (5 mg/kg Infusion), Randomised, Two-period Crossover Tolerability Study Carried Out in Healthy Male and Female Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 21 Sep 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ciclosporin (Primary)
  • Indications Amyotrophic lateral sclerosis; Chronic brain damage; Stroke
  • Focus Pharmacokinetics
  • Sponsors Abliva; NeuroVive Pharmaceutical

    • Most Recent Events

    • 20 Sep 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health: NCT01692834).
    • 30 Mar 2010 Primary endpoint 'Drug-bioavailability' has been met.
    • 30 Mar 2010 Status changed from active, no longer recruiting to completed as reported in a Neurovive media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top